mullarkey8k.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
________________
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of Earliest Event Reported) – November 18, 2009
 
________________________
 
WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)
_____________________

     
Pennsylvania
1-8036
23-1210010
(State or other jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
     
101 Gordon Drive, PO Box 645, Lionville, PA
  
19341-0645
(Address of principal executive offices)
  
(Zip Code)

 
(610) 594-2900
(Registrant’s telephone number, including area code)
 
Not Applicable
(Former name or address, if changed since last report)
____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


 
 
 


Item 5.02   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
 
West Pharmaceutical Services, Inc. today announced the departure of the Company’s chief operating officer Matthew T. Mullarkey, whose last day of employment was November 18, 2009.

Item 9.01   Financial Statements and Exhibits
 
(d)
Exhibits
    
       
 
Exhibit #
  
Description
       
 
99.1
  
West Pharmaceutical Services, Inc. Press Release, dated November 23, 2009.
 

 
 

 
 
 

 
 

 
2
 

 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 

 
WEST PHARMACEUTICAL SERVICES, INC.
 
/s/ John R. Gailey III
John R. Gailey III
Vice President, General Counsel and Secretary
 

 
 
November 23, 2009
 


 
3